Advanz Pharma (CXRXF) Downgraded to “Sell” at Zacks Investment Research

Share on StockTwits

Zacks Investment Research cut shares of Advanz Pharma (OTCMKTS:CXRXF) from a hold rating to a sell rating in a research note released on Tuesday morning, Zacks.com reports.

According to Zacks, “Advanz Pharma Corp. is a specialty pharmaceutical company. It operates primarily in Bridgetown, Barbados; London, England and Mumbai, through its subsidiaries. Advanz Pharma Corp., formerly known as Concordia International Corp., is based in LONDON, UNITED KINGDOM. “

Several other equities research analysts have also recently commented on the company. Bloom Burton restated a hold rating on shares of Advanz Pharma in a research note on Friday, March 15th. ValuEngine upgraded Advanz Pharma from a sell rating to a hold rating in a research note on Friday, March 1st.

Advanz Pharma stock opened at $17.23 on Tuesday. Advanz Pharma has a 12 month low of $14.40 and a 12 month high of $68.40. The company has a current ratio of 2.10, a quick ratio of 1.79 and a debt-to-equity ratio of 4.50.

Advanz Pharma Company Profile

ADVANZ PHARMA Corp., a specialty pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products. The company operates through two segments, Concordia International and Concordia North America. The Concordia International segment owns or licenses a portfolio of branded and generic prescription products to wholesalers, hospitals, and pharmacies.

Read More: Catch-Up Contributions

Get a free copy of the Zacks research report on Advanz Pharma (CXRXF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Advanz Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advanz Pharma and related companies with MarketBeat.com's FREE daily email newsletter.